July 1981

Relapse in Schizophrenia-Reply

Author Affiliations

Western Psychiatrie Institute and Clinic University of Pittsburgh School of Medicine 3811 O'Hara St Pittsburgh, PA 15261
Psychopharmacology Research Branch National Institute of Mental Health 5600 Fishers Lane Rockville, MD 20852

Arch Gen Psychiatry. 1981;38(7):843. doi:10.1001/archpsyc.1981.01780320123017

We thank Dr Goldhamer for making explicit yet another probable factor related to relapse among schizophrenic patients. His insights regarding the Kafka-like consequences of depot preparations are most relevant as the number of longacting neuroleptics multiply internationally and their application encompasses increasingly large populations of schizophrenic patients. The thrust of Dr Goldhamer's argument is that depot preparations would significantly lower relapse in the first year after discharge relative to oral medications if the psychological devastation and social consequences secondary to forced compliance were to be negotiated psychotherapeutically.

We, too, believe that the dysphoria that might follow on forced compliance is likely to be at least an intervening variable that contributes to the relapse of some patients, although empirical evidence for this conclusion regarding schizophrenic patients generally is indirect. Dr Goldhamer, however, draws attention to the important interface between pharmacological and psychotherapeutic strategies in the treatment of schizophrenia, an area frequently

First Page Preview View Large
First page PDF preview
First page PDF preview